STOCK TITAN

[Form 4/A] Immunic, Inc. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025. The amendment addresses two significant transactions:

  • Stock Purchase: Acquired 15,000 shares of common stock at $0.77 per share on June 4, 2025, bringing direct ownership to 29,000 shares
  • Stock Option Grant: Received 1,558,000 stock options on June 5, 2025, with an exercise price of $0.7729, expiring June 5, 2035

The options vest 25% after one year, with remaining shares vesting monthly over 36 months. Vitt also maintains indirect ownership of 362,877 shares through Listrax UG, where he serves as Managing Director. The amendment specifically corrects an administrative error regarding the number of stock options granted in the original filing.

Il CEO di Immunic, Daniel Vitt, ha presentato un Modulo 4 modificato il 28 giugno 2025, correggendo un precedente Modulo 4 inviato il 6 giugno 2025. La modifica riguarda due operazioni importanti:

  • Acquisto di Azioni: Acquisite 15.000 azioni ordinarie al prezzo di 0,77$ per azione il 4 giugno 2025, portando la proprietà diretta a 29.000 azioni
  • Concessione di Opzioni su Azioni: Ricevute 1.558.000 opzioni su azioni il 5 giugno 2025, con un prezzo di esercizio di 0,7729$, con scadenza il 5 giugno 2035

Le opzioni maturano il 25% dopo un anno, mentre le restanti azioni maturano mensilmente nel corso di 36 mesi. Vitt detiene inoltre una proprietà indiretta di 362.877 azioni tramite Listrax UG, dove ricopre il ruolo di Amministratore Delegato. La modifica corregge specificamente un errore amministrativo riguardante il numero di opzioni su azioni concesse nella dichiarazione originale.

El CEO de Immunic, Daniel Vitt, presentó un Formulario 4 enmendado el 28 de junio de 2025, corrigiendo un Formulario 4 previamente presentado el 6 de junio de 2025. La enmienda aborda dos transacciones importantes:

  • Compra de Acciones: Adquirió 15,000 acciones comunes a $0.77 por acción el 4 de junio de 2025, elevando la propiedad directa a 29,000 acciones
  • Concesión de Opciones sobre Acciones: Recibió 1,558,000 opciones sobre acciones el 5 de junio de 2025, con un precio de ejercicio de $0.7729, que vencen el 5 de junio de 2035

Las opciones se consolidan en un 25% después de un año, y las acciones restantes se consolidan mensualmente durante 36 meses. Vitt también mantiene una propiedad indirecta de 362,877 acciones a través de Listrax UG, donde es Director General. La enmienda corrige específicamente un error administrativo relacionado con la cantidad de opciones sobre acciones otorgadas en la presentación original.

Immunic CEO 다니엘 비트(Daniel Vitt)는 2025년 6월 28일에 이전에 제출한 2025년 6월 6일자 Form 4를 수정한 Form 4를 제출했습니다. 이번 수정은 두 가지 주요 거래를 다룹니다:

  • 주식 매입: 2025년 6월 4일에 보통주 15,000주를 주당 0.77달러에 매입하여 직접 소유주식이 29,000주가 되었습니다
  • 스톡 옵션 부여: 2025년 6월 5일에 행사가 0.7729달러인 스톡 옵션 1,558,000주를 받았으며, 만료일은 2035년 6월 5일입니다

옵션은 1년 후 25%가 베스팅되며, 나머지 주식은 36개월 동안 매월 베스팅됩니다. 비트는 또한 자신이 전무이사로 있는 Listrax UG를 통해 362,877주를 간접 소유하고 있습니다. 이번 수정은 원래 제출서에 기재된 스톡 옵션 수에 대한 행정적 오류를 바로잡기 위한 것입니다.

Le PDG d'Immunic, Daniel Vitt, a déposé un formulaire 4 modifié le 28 juin 2025, corrigeant un formulaire 4 précédemment soumis le 6 juin 2025. L'amendement concerne deux transactions importantes :

  • Achat d'actions : Acquisition de 15 000 actions ordinaires à 0,77 $ par action le 4 juin 2025, portant la propriété directe à 29 000 actions
  • Attribution d'options d'achat d'actions : Réception de 1 558 000 options d'achat d'actions le 5 juin 2025, avec un prix d'exercice de 0,7729 $, expirant le 5 juin 2035

Les options acquièrent 25 % de droits après un an, les actions restantes étant acquises mensuellement sur 36 mois. Vitt détient également une propriété indirecte de 362 877 actions via Listrax UG, où il est directeur général. L'amendement corrige spécifiquement une erreur administrative concernant le nombre d'options attribuées dans la déclaration initiale.

Immunic CEO Daniel Vitt reichte am 28. Juni 2025 ein berichtigt Form 4 ein, um ein zuvor am 6. Juni 2025 eingereichtes Form 4 zu korrigieren. Die Änderung betrifft zwei bedeutende Transaktionen:

  • Aktienkauf: Erwerb von 15.000 Stammaktien zum Preis von 0,77 USD pro Aktie am 4. Juni 2025, wodurch der direkte Besitz auf 29.000 Aktien anstieg
  • Aktienoptionsgewährung: Erhielt am 5. Juni 2025 1.558.000 Aktienoptionen mit einem Ausübungspreis von 0,7729 USD, gültig bis zum 5. Juni 2035

Die Optionen werden zu 25 % nach einem Jahr fällig, die restlichen Anteile vesten monatlich über 36 Monate. Vitt hält zudem indirekt 362.877 Aktien über Listrax UG, wo er als Geschäftsführer tätig ist. Die Änderung korrigiert speziell einen administrativen Fehler bezüglich der Anzahl der ursprünglich gewährten Aktienoptionen.

Positive
  • CEO Daniel Vitt made a direct open market purchase of 15,000 shares at $0.77 per share, demonstrating insider confidence
  • CEO received a significant stock option grant of 1,558,000 shares at $0.7729, aligning long-term interests with shareholders
Negative
  • None.

Il CEO di Immunic, Daniel Vitt, ha presentato un Modulo 4 modificato il 28 giugno 2025, correggendo un precedente Modulo 4 inviato il 6 giugno 2025. La modifica riguarda due operazioni importanti:

  • Acquisto di Azioni: Acquisite 15.000 azioni ordinarie al prezzo di 0,77$ per azione il 4 giugno 2025, portando la proprietà diretta a 29.000 azioni
  • Concessione di Opzioni su Azioni: Ricevute 1.558.000 opzioni su azioni il 5 giugno 2025, con un prezzo di esercizio di 0,7729$, con scadenza il 5 giugno 2035

Le opzioni maturano il 25% dopo un anno, mentre le restanti azioni maturano mensilmente nel corso di 36 mesi. Vitt detiene inoltre una proprietà indiretta di 362.877 azioni tramite Listrax UG, dove ricopre il ruolo di Amministratore Delegato. La modifica corregge specificamente un errore amministrativo riguardante il numero di opzioni su azioni concesse nella dichiarazione originale.

El CEO de Immunic, Daniel Vitt, presentó un Formulario 4 enmendado el 28 de junio de 2025, corrigiendo un Formulario 4 previamente presentado el 6 de junio de 2025. La enmienda aborda dos transacciones importantes:

  • Compra de Acciones: Adquirió 15,000 acciones comunes a $0.77 por acción el 4 de junio de 2025, elevando la propiedad directa a 29,000 acciones
  • Concesión de Opciones sobre Acciones: Recibió 1,558,000 opciones sobre acciones el 5 de junio de 2025, con un precio de ejercicio de $0.7729, que vencen el 5 de junio de 2035

Las opciones se consolidan en un 25% después de un año, y las acciones restantes se consolidan mensualmente durante 36 meses. Vitt también mantiene una propiedad indirecta de 362,877 acciones a través de Listrax UG, donde es Director General. La enmienda corrige específicamente un error administrativo relacionado con la cantidad de opciones sobre acciones otorgadas en la presentación original.

Immunic CEO 다니엘 비트(Daniel Vitt)는 2025년 6월 28일에 이전에 제출한 2025년 6월 6일자 Form 4를 수정한 Form 4를 제출했습니다. 이번 수정은 두 가지 주요 거래를 다룹니다:

  • 주식 매입: 2025년 6월 4일에 보통주 15,000주를 주당 0.77달러에 매입하여 직접 소유주식이 29,000주가 되었습니다
  • 스톡 옵션 부여: 2025년 6월 5일에 행사가 0.7729달러인 스톡 옵션 1,558,000주를 받았으며, 만료일은 2035년 6월 5일입니다

옵션은 1년 후 25%가 베스팅되며, 나머지 주식은 36개월 동안 매월 베스팅됩니다. 비트는 또한 자신이 전무이사로 있는 Listrax UG를 통해 362,877주를 간접 소유하고 있습니다. 이번 수정은 원래 제출서에 기재된 스톡 옵션 수에 대한 행정적 오류를 바로잡기 위한 것입니다.

Le PDG d'Immunic, Daniel Vitt, a déposé un formulaire 4 modifié le 28 juin 2025, corrigeant un formulaire 4 précédemment soumis le 6 juin 2025. L'amendement concerne deux transactions importantes :

  • Achat d'actions : Acquisition de 15 000 actions ordinaires à 0,77 $ par action le 4 juin 2025, portant la propriété directe à 29 000 actions
  • Attribution d'options d'achat d'actions : Réception de 1 558 000 options d'achat d'actions le 5 juin 2025, avec un prix d'exercice de 0,7729 $, expirant le 5 juin 2035

Les options acquièrent 25 % de droits après un an, les actions restantes étant acquises mensuellement sur 36 mois. Vitt détient également une propriété indirecte de 362 877 actions via Listrax UG, où il est directeur général. L'amendement corrige spécifiquement une erreur administrative concernant le nombre d'options attribuées dans la déclaration initiale.

Immunic CEO Daniel Vitt reichte am 28. Juni 2025 ein berichtigt Form 4 ein, um ein zuvor am 6. Juni 2025 eingereichtes Form 4 zu korrigieren. Die Änderung betrifft zwei bedeutende Transaktionen:

  • Aktienkauf: Erwerb von 15.000 Stammaktien zum Preis von 0,77 USD pro Aktie am 4. Juni 2025, wodurch der direkte Besitz auf 29.000 Aktien anstieg
  • Aktienoptionsgewährung: Erhielt am 5. Juni 2025 1.558.000 Aktienoptionen mit einem Ausübungspreis von 0,7729 USD, gültig bis zum 5. Juni 2035

Die Optionen werden zu 25 % nach einem Jahr fällig, die restlichen Anteile vesten monatlich über 36 Monate. Vitt hält zudem indirekt 362.877 Aktien über Listrax UG, wo er als Geschäftsführer tätig ist. Die Änderung korrigiert speziell einen administrativen Fehler bezüglich der Anzahl der ursprünglich gewährten Aktienoptionen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vitt Daniel

(Last) (First) (Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and Director
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/06/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/04/2025 P 15,000 A $0.77(1) 29,000 D
Common Stock 362,877 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $0.7729 06/05/2025 A 1,558,000 (3) 06/05/2035 Common Stock 1,558,000 $0.00 1,558,000 D
Explanation of Responses:
1. The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).
2. 362,877 shares of the Issuer's common stock are owned by Listrax UG (haftungsbeschrankt). The RP is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.
3. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.
Remarks:
This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 6, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.
/s/ Daniel Vitt 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IMUX shares did CEO Daniel Vitt purchase on June 4, 2025?

CEO Daniel Vitt purchased 15,000 shares of IMUX common stock at a price of $0.77 per share on June 4, 2025. The purchase was made in Euros and converted to USD at an exchange rate of 1 Euro = $1.1384.

What stock options were granted to IMUX's CEO in June 2025?

On June 5, 2025, Daniel Vitt was granted 1,558,000 stock options with an exercise price of $0.7729. The options vest 25% after one year, with the remainder vesting in equal monthly increments over the following 36 months. The options expire on June 5, 2035.

What is the total IMUX stock ownership of CEO Daniel Vitt after the reported transactions?

Following the reported transactions, Daniel Vitt directly owns 29,000 shares of IMUX common stock and indirectly controls 362,877 shares through Listrax UG (where he serves as Managing Director). He also holds 1,558,000 stock options.

Why did IMUX file a Form 4/A amendment on June 28, 2025?

IMUX filed the Form 4/A to amend the original Form 4 filed on June 6, 2025, correcting an administrative error that incorrectly reported the number of stock options granted to CEO Daniel Vitt.

What indirect ownership of IMUX stock does Daniel Vitt have?

Daniel Vitt indirectly owns 362,877 shares of IMUX common stock through Listrax UG (haftungsbeschrankt), where he serves as Managing Director and exercises voting and dispositive power over the shares.
Immunic Inc

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Latest SEC Filings

IMUX Stock Data

67.84M
94.52M
1.04%
59.43%
2.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK